EASL announced the formation and official launch of MICROB-PREDICT, a project designed to research the human microbiome for clinical research and therapeutic development in the field of decompensated cirrhosis and acute-on-chronic liver failure, according to a press release.
The project was financed by EU Horizon 2020 with 15 million euros and will include a 22-member multinational and multidisciplinary consortium of world-leading microbiome specialists, clinical experts and patient organizations.
“One of our aims is to find the microbiome signatures of decompensation of cirrhosis and predict the development of ACLF,” Jonel Trebicka, MD, PhD, scientific coordinator of the MICROB-PREDICT consortium, said in the release. “Moreover, this project will develop point-of-care devices to predict the response to specific treatments in these patients. The project has the potential to change the clinical practice towards more personalized medicine.”
The MICROB-PREDICT project will base the development of biomarkers on data from three existing EU-funded projects including GALAXY, LIVERHOPE, and PREDICT, over a 75-month period.